Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Thursday 12 October 2017, 10:03 to 13:03

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Stephen O’Brien (Chair) Present for all notes
2. John Cairns Present for all notes
3. Mr Michael Chambers Present for all notes
4. David Chandler Present for all notes
5. Gail Coster Present for all notes
6. Dr Prithviraj Das Present for all notes
7. Mr John Hampson Present for all notes
8. Dr Nigel Langford Present for all notes
9. Professor Andrea Manca Present for notes 01 to 13
10. Richard Nicholas Present for all notes
11. Chris O’Regan Present for all notes
12. Dr Peter Selby Present for all notes
13. Professor Andrew Stevens Present for all notes
14. Robert Walton Present for all notes
15. Dr Judith Wardle Present for all notes

In attendance:

Alex Filby Technical Adviser, National Institute for Health and Clinical Excellence Present for all notes

Sana Khan Technical Lead, National Institute for Health and Care Excellence Present for all notes

Tanith Musson Administrator, National Institute for Health and Care Excellence Present for all notes

Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Yates Project Manager, National Institute for Health and Care Excellence Present for all notes
Non-public observers:

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Carroll</td>
<td>ERG representative</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Christopher Eatough</td>
<td>NICE Observer</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Leslie Hayes</td>
<td>NICE Observer</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Alex Langridge</td>
<td>External Observer</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Andrew Langford</td>
<td>Patient Expert</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Inderjit Mandair</td>
<td>Company representative</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Tim Meyer</td>
<td>Clinical Expert</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Jessica Nangle</td>
<td>NICE Observer</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Frances Nixon</td>
<td>NICE Observer</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Matt Stevenson</td>
<td>ERG representative</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Paul Tappenden</td>
<td>ERG representative</td>
<td>Present for notes 01 - 13</td>
</tr>
<tr>
<td>Bernard Wilson</td>
<td>Company representative</td>
<td>Present for notes 01 - 13</td>
</tr>
</tbody>
</table>

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of regorafenib for previously treated unresectable hepatocellular carcinoma

2. The Chair informed the Committee of the non-public observers at this meeting: Christopher Eatough, Leslie Hayes, Alex Langridge, Jessica Nangle and Frances Nixon

3. Apologies were received from Professor Kathryn Abel, Professor Andrew Renehan and Dr Derek Ward

Any other Business

4. None

Appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma [ID991]

Part 1 – Open session

5. The Chair welcomed the invited experts: Chris Carroll, Andrew Langford, Tim Meyer, Professor Matt Stevenson and Dr Paul Tappenden to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Bayer Plc to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Chair Stephen O’Brien, John Cairns, Dr Michael Chambers, David Chandler, Gail Coster, Dr Prithviraj Das, Mr John Hampson, Dr Nigel Langford, Professor Andrea Manca, Richard Nicholas, Chris O’Regan, Dr...
Peter Selby, Professor Andrew Stevens, Robert Walton and Dr Judith Wardle all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma.

7.2. It was noted that Committee members Professor Matt Stevenson and Dr Paul Tappenden were serving as ERG representatives and were therefore absent from the Committee.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of regorafenib for previously treated unresectable hepatocellular carcinoma.

9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Andrew Langford declared a personal non-specific financial interest as he had previously received funding from Bayer Plc.

9.1.1. It was agreed that this declaration would not prevent Andrew Langford from participating in this section of the meeting.

9.2. Tim Meyer declared a personal non-specific financial interest as he had previously served on advisory boards for companies which included Bayer Plc, and worked on a trial which received an unrestricted grant from Bayer Plc.

9.2.1. It was agreed that this declaration would not prevent Tim Meyer from participating in this section of the meeting.

10. The Chair introduced the lead team, Gail Coster, Dr Prithwiraj Das, and Dr Judith Wardle, who gave presentations on the clinical effectiveness and cost effectiveness of regorafenib for previously treated unresectable hepatocellular carcinoma.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of regorafenib for previously treated unresectable hepatocellular carcinoma.

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

17. 10:00am Tuesday 12 December 2017 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.